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Renal damage associated with proteinuria. Experimental stud- should be beneficial for the kidney. A growing number
ies have demonstrated that proteins filtered by the glomerulus of prospective clinical studies, most of them based on
induce a proliferation of proximal tubular cells accompanied by the antiproteinuric properties of drugs that block thean increased synthesis of many vasoactive and proinflammatory
renin-angiotensin system (RAS), such as ACE inhibitorssubstances. The appearance of interstitial cellular infiltrates, a
(ACEI) and angiotensin II type 1 (AT1) receptor antago-well-known finding in proteinuric diseases, precedes progressive
tubulointerstitial fibrosis. Activation of the transcription factor nists (ARA), has confirmed the validity of this premise.
B (NF-B) plays a pivotal role in the renal damage induced
by proteinuria. In this scenario, any therapeutic intervention
that reduces proteinuria should be beneficial for the kidney. MECHANISMS OF TUBULOINTERSTITIAL
Drugs that block the renin-angiotensin system [angiotensin DAMAGE INDUCED BY PROTEINURIA
converting enzyme (ACE) inhibitors and angiotensin II recep-
Proteins filtered by the glomerulus are reabsorbed bytor antagonists (ARA)] have repeatedly shown striking anti-
proteinuric and renoprotective properties, both in experimen- proximal tubular cells (PTC) and the mechanisms in-
tal and clinical studies. Studies in patients with type 1 and type volved have been recently clarified [8]. Albumin protein
2 diabetic nephropathy as well as in non-diabetic nephropathies
receptors (megalin, cubilin) have been identified on thehave confirmed that the renoprotection obtained with ACEI/
apical surface of PTC. Binding of albumin is followedARA is closely related with their antiproteinuric effect and
is largely independent of blood pressure changes. However, by receptor-mediated endocytosis and degradation by
resistance to the antiproteinuric effect of ACEI/ARA is a com- lysosomes. It has been shown that the turnover of tubular
mon clinical observation. Several therapeutic measures (that is, cells is markedly increased in rat models of proteinuria.adequate blood pressure control, early introduction of ACEI/
Similarly, human tubular cells proliferated when proteinsARA, dietary protein restriction, low salt diets, weight loss in
were added to the apical medium [9]. These proliferativeoverweight patients, addition of a diuretic, increasing ACEI/
ARA dose titrated against proteinuria levels, combined ther- responses are accompanied by a concentration-depen-
apy ACEI plus ARA, addition of drugs with antiproteinuric dent increases in the rate of synthesis of several vaso-
effect such as non-dihydropiridine calcium channel blockers
active and proinflammatory substances. An increasedor NSAIDs) may increase the proteinuria reduction induced
synthesis of endothelin-1, RANTES (regulated upon ac-by ACEI and ARA.
tivation normal T-cell expressed and secreted), mono-
cyte chemoattractant protein 1 (MCP-1) and osteopontin
has been repeatedly shown in experimental models ofSeveral prospective clinical studies have shown that
proteinuric diseases and in human PTC incubated withthe level of proteinuria is closely related to the rate
proteins [10, 11]. The release of these substances leadsof renal failure progression, both in diabetic and non-
to the migration of macrophages and T lymphocytes intodiabetic chronic nephropathies [1–5]. In recent years, a
renal interstitium where they promote synthesis of extra-growing number of experimental studies have demon-
cellular matrix proteins and fibrosis. The appearance ofstrated that proteins filtered by the glomerulus cause
injury of tubular cells, leading to progressive tubulointer- striking interstitial cellular infiltrates is a well-known
stitial fibrosis [reviewed in 6, 7]. Therefore, proteinuria finding in renal biopsies of proteinuric patients and sev-
should be considered not merely as a marker of the eral studies suggest that they play a key role in the devel-
severity of glomerular injury, but also as a direct tubulo- opment of tubulointerstitial damage associated with pro-
toxic agent itself; following this hypothesis, any therapeu- teinuria [12]. Interstitial macrophages are a source of
tic intervention that induces a proteinuria decrease several vasoactive, fibrosis-promoting growth factors and
cytokines that activate the recruitment of myofibroblasts.
Interstitial fibroblasts and myofibroblasts produce extra-Key words: progressive renal disease, angiotensin converting enzyme
cellular matrix proteins that cause the appearance ofinhibitors, angiotensin receptor blockers, tubulointerstitial fibrosis, in-
terstitial cellular infiltrates. progressive fibrosis. Interstitial macrophages, along with
tubular cells and myofibroblasts are a source of trans- 2002 by the International Society of Nephrology
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forming-growth factor- (TGF-), the most important Nevertheless, those patients with no antiproteinuric re-
sponse to ACEI or with only a modest reduction of thefibrogenic cytokine identified so far. Interstitial macro-
phages also produce tissue inhibitor of metalloprotein- baseline proteinuria levels did not obtain benefits from
this treatment regarding the progression of renal failure.ase-1 (TIMP-1) and plasminogen activator inhibitor-1
(PAI-1), substances that inhibit degradation of extracel- The most important clinical corollaries of these studies
were that the degree of the initial proteinuria decreaselular matrix proteins by proteases.
The pathways through which filtered proteins induce obtained by ACEI largely predicts the long-term out-
come of renal function, and that in the absence of athese up-regulated syntheses of proinflammatory and fi-
brogenic substances are partially unknown, but several significant proteinuria decrease no beneficial influences
of this treatment can be observed on the progression ofstudies suggest a key role for the transcription factor,
nuclear factor-B (NF-B) in the pathogenesis of renal renal disease.
Several large, prospective studies have demonstrateddamage associated with proteinuria [13, 14]. NF-B is
present in virtually every cell type, including PTC, al- that ACE inhibition significantly slows the progression
of renal failure, both in diabetic and non-diabetic renalthough in an inactive form. Upon stimulation, NF-B is
released from an inhibitory subunit (IB) and promotes diseases [20–23]. Importantly, and confirming the initial
studies, the beneficial effect on the rate of GFR declinethe transcriptional activation of a large number of target
genes that include RANTES, interleukin (IL)-1, IL-2, has shown a close correlation with the degree of protein-
uria reduction, whereas it has been largely independentIL-6, monocyte chemoattractant protein-1 (MCP-1), tu-
mor necrosis factor (TNF), adhesion molecules, and sev- from the control of blood pressure. We have recently
analyzed (unpublished data) the long-term evolution oferal other proinflammatory substances. NF-B plays a
pivotal role in a large variety of inflammatory diseases a cohort of 19 patients with different types of chronic
proteinuric renal diseases that were treated with ACEIand recent studies have stressed its implications in the
pathogenesis of different types of renal damage. Cul- in spite of a systolic blood pressure115 mm Hg (initial
mean BP 82  3 mm Hg). Initial ACEI doses were lowtured PTC incubated with high albumin concentrations
show a concentration-dependent NF-B increase and (such as captopril 12.5 mg/day, enalapril 2.5 mg/day) and
well tolerated. By the first month of treatment protein-activation of NF-B has been demonstrated in adrya-
micin-induced nephrosis In this latter model, treatment uria had decreased to 50% of the baseline values, without
significant changes of renal function or blood pressure.with antioxidant drugs that block NF-B activation pre-
vented the appearance of tubulointerstitial damage in The sustained decrease in proteinuria and a stable renal
function were observed during follow-up (48 27 months)spite of the persistence of proteinuria [15]. Interestingly,
NF-B activation is decreased by ACE inhibitors, which and the patients tolerated the increasing ACEI doses
without complications. ACE inhibitors, therefore, alsoare drugs with well-known antiproteinuric properties [16].
induce their antiproteinuric and renoprotective effects
in patients with normal/low levels of blood pressure.
PROTEINURIA DECREASE
AND RENOPROTECTION
AT1 RECEPTOR ANTAGONISTS (ARA)ACE inhibitors
Diabetic nephropathyThe accumulating evidence of a direct tubulointersti-
tial damage induced by proteinuria was reinforced with Recent prospective and randomized studies with irbe-
sartan and losartan have demonstrated that these drugsexperimental studies showing that those therapeutic mea-
sures that reduce the level of proteinuria were accompa- were effective in delaying the progression of type 2 dia-
betic nephropathy, reducing significantly the risk of anied by beneficial effects on the progression of different
models of renal diseases. Most of these experimental data doubling of the serum creatinine concentration and the
risk of end-stage renal disease in comparison with pla-were obtained with ACEI, drugs that showed strong anti-
proteinuric and renoprotective effects [reviewed in 17]. cebo or other antihypertensive agents [24, 25]. Protein-
uria decreased by 33 to 35% and, as in the studies withInitial clinical observations confirmed the antiprotein-
uric effect of ACEI both in diabetic and non-diabetic ACEI, the renal protection was independent of the re-
duction in blood pressure caused by these drugs. ARAnephropathies [18, 19]. Proteinuria decrease induced by
ACEI is already observed within the first weeks of treat- also were effective in preventing the development of dia-
betic nephropathy in hypertensive patients with type 2ment, although a marked variability in the antiprotein-
uric response has been observed. Initial studies following diabetes and microalbuminuria [26]. These studies con-
firmed the results of experimental investigations thatthe evolution of renal function after the introduction of
ACEI demonstrated that the rate of renal failure pro- have shown strong beneficial effects of ARA on several
types of experimental renal diseases, including diabeticgression was significantly slowed or even arrested in those
patients showing an important proteinuria decrease [3, 4]. nephropathy [17]. Therefore, inhibition of RAS, either
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Table 1. Therapeutic measures that may increase the antiproteinuricby ACEI or by ARA, conferred significant protective
and renoprotective effects of renin-angiotensin system by
and antiproteinuric effects on both type 1 and type 2 angiotensin converting enzymes (ACE) inhibitors or
angiotensin II receptor antagonists (ARA)diabetic nephropathy.
Adequate specific therapy for every different renal diseaseNon-diabetic nephropathies Adequate blood pressure control
Early onset of ACEI/ARA treatmentAngiotensin II type 1 receptor antagonists have shown
Dietary protein restrictionan antiproteinuric effect on some studies including a short Low salt diets
number of patients [27]. In a double blind, randomized Weight loss in overweight patients
Addition of a diuretictrial, recently performed in several centers from Spain (un-
Increasing doses of ACEI or ARA titrated against proteinuria levelspublished data), 97 patients with different types of non- Combination therapy (ARA added to an ACEI or vice versa)
diabetic nephropathies and proteinuria higher than 1.5 g/ Nondihydropiridine calcium channel blockers
Nonsteroidal antiinflammatory agents (NSAIDs)24 h were randomized to losartan or amlodipine during
20 weeks. Proteinuria decreased by 50.4% after 20 weeks
in the losartan group, whereas no significant changes were
observed in the amlodipine group. There were no differ-
but they are not the panacea for every patient with aences in the blood pressure reduction achieved by both
proteinuric renal disease: a significant number of patientstreatments and the antiproteinuric effect of losartan was
do not exhibit proteinuria reduction nor stabilization ofindependent of blood pressure changes. Urinary excretion
GFR after the introduction of ACEI/ARA, and the causesof transforming growth factor- (TGF-) significantly de-
of this therapeutic failure remained largely unknown.creased with losartan (22.4%), whereas it tended to in-
Several therapeutic interventions that have been reportedcrease with amlodipine. A significant correlation between
as useful for increasing the response to ACEI/ARAproteinuria decrease and urinary TGF- reduction was
treatments are listed in Table 1. Obviously, ACEI/ARAfound in the losartan group. The subanalysis of the differ-
represent a general, non-specific treatment, that shouldent renal diseases included in the study confirmed a strong
not lead to the oversight of specific therapies indicatedantiproteinuric effect of losartan in patients with IgA
in many proteinuric nephropathies (such as, immunosup-nephropathy (55.4%), membranous glomerulonephri-
pressive treatment in aggressive glomerulonephritis withtis (28.9%), focal glomerulosclerosis (46.9%) and
nephrotic syndrome, continuous adjustment of immuno-hypertensive nephroangiosclerosis (62.9%) in compar-
suppressive therapy in SLE, etc). Although ACEI/ARAison with patients with the same diagnosis randomized
confer greater renoprotection than other antihyperten-to amlodipine group. Urinary TGF- also showed a de-
sive agents in proteinuric renal disease, it should notcrease in every diagnostic subgroup. Considering the re-
be forgotten that lowering of blood pressure in generalsults of previous studies (in which an early decrease in
results in lowering of protein excretion and long-termproteinuria was an excellent predictor of the beneficial
beneficial effects in any hypertensive chronic nephropa-influences of ACEI), the dramatic antiproteinuric effect
thy. According to the results of the Modification of Dietobserved with losartan should be interpreted as a sign
in Renal Disease (MDRD) Study [2], blood pressureof long-term renoprotection afforded by ARA in non-
control should be targeted to values 130/80 mm Hg indiabetic nephropathies. In addition, the urinary decrease
patients with proteinuric nephropathies. ACEI or ARAof TGF- is of interest taking into account the strong
should be the basis of antihypertensive therapy; however,fibrogenic properties of this growth factor, and previous
if the recommended target is not reached with thesestudies that found a correlation between urinary TGF-
agents, other antihypertensive drugs should be added.decrease and long-term renoprotection [28].
Prospective studies have demonstrated that ACEI/ARA
can avoid the progression from microalbuminuria to
PROTEINURIA DECREASE AS A TARGET IN overt nephropathy in diabetic patients [26], and we have
THE MANAGEMENT OF CHRONIC obtained excellent results [Kaplan-Meier renal survival,
PROTEINURIC NEPHROPATHIES defined as the absence of a serum creatinine (SCr) in-
crease50% of baseline values, 100% at five years] inThe compelling evidence provided in the earlier sum-
marized clinical studies indicates that the level of pro- patients with IgA nephropathy and SCr 1.5 mg/dL that
started ACEI treatment when proteinuria reached 1 g/24 hteinuria represents an excellent target to monitor the
effectiveness of renoprotective therapy with ACEI or (abstract; Gonza´lez et al, J Am Soc Nephrol 12:102A,
2001). We think that ACEI/ARA should be started inARA. Proteinuria should be reduced as far as possible,
although no clinical studies have been performed to de- every patient with significant proteinuria (0.5 to 1 g/24)
unless specific contraindications and preferably beforefine the level of proteinuria below which renal function
would remain stable. ACEI/ARA treatment significantly the onset of GFR decline. The antiproteinuric effect of
ACEI/ARA is enhanced by dietary protein restrictiondecreased the risk of renal failure progression [20–26],
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5. Jafar TH, Stark PC, Schmid CH, et al: Proteinuria as a modifiable[29], a low-sodium diet [19] and by the addition of a
risk factor for the progression of non-diabetic renal diseases. Kid-
diuretic [30]. We have observed that patients with obe- ney Int 60:1131–1140, 2001
sity-related nephropathies exhibit a poor response to 6. Remuzzi G, Bertani T: Pathophysiology of progressive nephropa-
thies. N Engl J Med 339:1448–1456, 1998ACEI treatment on the long-term follow-up [31] and that
7. Remuzzi G, Ruggenenti P, Benigni A: Understanding the naturea moderate weight loss induces a significant proteinuria of renal disease progression. Kidney Int 51:2–15, 1997
reduction in overweight patients with different types of 8. Brunskill NJ: Mechanisms of albumin uptake by proximal tubular
cells. Am J Kidney Dis 37(Suppl 2):S17–S20, 2001proteinuric nephropathies (abstract; Morales et al, J Am
9. Burton CJ, Harper SJ, Bailey E, et al: Turnover of human tubularSoc Nephrol 12:231, 2001). Therefore, low calorie diets
cells exposed to proteins in vivo and in vitro. Kidney Int 59:507–514,
in overweight patients and prevention of weight gain 2001
10. Eddy A: Molecular insights into renal interstitial fibrosis. J Amshould be another therapeutic target additive to ACEI/
Soc Nephrol 7:2495–2508, 1996ARA in proteinuric diseases. The dose of these drugs
11. Abbate M, Zoja C, Corna D, et al: In progressive nephropathies,
should be titrated against urinary protein excretion apart overload of tubular cells with filtered proteins translates glomerular
permeability dysfunction into cellular signals of interstitial in-from their antihypertensive action and some studies have
flammation. J Am Soc Nephrol 9:1213–1224, 1998shown that increasing the dose of ACEI/ARA further
12. Eddy A. Role of cellular infiltrates in response to proteinuria. Am
reduces proteinuria [27]. In the last two meetings of the J Kidney Dis 37(Suppl2): S25–S29, 2001
ASN, more than twenty communications addressed the 13. Zoja Z, Donadelli R, Colleoni S, et al: Protein overload stimu-
lates RANTES production by proximal tubular cells dependingissue of combined therapy with an ACEI and an ARA;
on NF-B activation. Kidney Int 53:1608–1615, 1998most of them found that combined therapy had a stronger 14. Guijarro C, Egido J: Transcription factor-B (NF-B) and renal
antiproteinuric effect than single therapy with maximal disease. Kidney Int 59:415–424, 2001
15. Rangan G, Wang Y, Tay Y, Harris DCH: Inhibition of nucleardose of an ACEI or an ARA. While published studies
factor-B activation reduces cortical tubulointerstitial injury inhave reported contradictory results [32, 33], until a large,
proteinuric rats. Kidney Int 56:118–134, 1999
prospective study definitely clarifies this issue, we think 16. Morrisey JJ, Klahr S: Enalapril decreases nuclear factor B acti-
vation in the kidney with ureteral obstruction. Kidney Int 52:926–that the addition of an ARA to patients who do not
933, 1997show an adequate antiproteinuric response to maximal
17. Taal MW, Brenner BM: Renoprotective benefits of RAS inhibi-
therapeutic dose of ACEI or the reverse (addition of an tion: From ACEI to angiotensin II antagonists. Kidney Int 57:1803–
1817, 2000ACEI to ARA treated patients) is a recommendable
18. Taguma Y, Kitamoto Y, Futaki G, et al: Effect of captopril inapproach. It has been reported that non-dihydropiridine
heavy proteinuria in azotemic diabetes. N Engl J Med 313:1617–
calcium channel blockers (diltiazem, verapamil) induce 1620, 1985
a specific proteinuria decrease. Most of these studies 19. Heeg JE, De Jong PE, Van der Hem GK, et al: Efficacy and
variability of the antiproteinuric effect of ACE inhibition by lisino-were performed in hypertensive type 2 diabetic patients
pril. Kidney Int 36:272–279, 1989with overt nephropathy [34]. Nevertheless, verapamil was 20. Lewis EJ, Hunsicker L, Bain RP, Rhode RP, for the Collaborative
not as effective as an ACEI in reducing proteinuria in Study Group: The effect of angiotensin-converting-enzyme inhibi-
tion on diabetic nephropathy. N Engl J Med 329:1456–1462, 1993non-diabetic patients [35]. Non-steroidal anti-inflamma-
21. Maschio G, Alberti D, Janin G et al: Effect of the angiotensin-tory drugs (NSAIDs) have shown a considerable antipro- converting-enzyme inhibitor benazepril on the progression of
teinuric efficacy both in experimental and clinical studies chronic renal insufficiency. N Engl J Med 334: 939–945, 1996
22. The GISEN Group: Randomised placebo-controlled trial of effect[36], but concerns about their short- and long-term side
of ramipril on declining in glomerular filtration rate and risk ofeffects thus far have precluded their combination with
terminal renal failure in proteinuric, non-diabetic nephropathy.
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